28277189|t|CXCL5 Plays a Promoting Role in Osteosarcoma Cell Migration and Invasion in Autocrine - and Paracrine -Dependent Manners
28277189|a|CXCL5, a CXC-type chemokine, is an important attractant for granulocytic immune cells by binding to its receptor CXCR2. Recently, CXCL5 / CXCR2 has been found to play an oncogenic role in many human cancers. However, the exact role of CXCL5 in osteosarcoma cell migration and invasion has not been revealed. Here we found that the protein expression of CXCL5 was significantly increased in osteosarcoma tissues compared with that in matched adjacent nontumor tissues. Moreover, the expression of CXCL5 was significantly associated with advanced clinical stage and metastasis. Further investigation showed that the CXCL5 expression levels were also significantly increased in osteosarcoma cell lines, including Saos-2, MG63, U2OS, and SW1353, when compared with those in normal osteoblast hFoB1.19 cells. U2OS cells were further transfected with CXCL5 - specific siRNA or overexpression plasmid. Knockdown of CXCL5 significantly suppressed U2OS cell migration and invasion. On the contrary, overexpression of CXLC5 remarkably promoted the migration and invasion of U2OS cells. Interestingly, both exogenous CXCL5 treatment and the conditioned medium of CXCL5 - overexpressing hFoB1.19 cells could also enhance the migration and invasion of U2OS cells, suggesting that the promoting role of CXCL5 in U2OS cell migration and invasion is also in a paracrine -dependent manner. According to these data, our study demonstrates that CXCL5 is upregulated in osteosarcoma and may play an oncogenic role in osteosarcoma metastasis. Therefore, CXCL5 may become a potential therapeutic target for osteosarcoma treatment.
28277189	0	5	CXCL5	T116,T123	C1955899
28277189	32	44	Osteosarcoma	T191	C0029463
28277189	45	72	Cell Migration and Invasion	T191	C0027627
28277189	76	85	Autocrine	T042	C0596138
28277189	92	101	Paracrine	T039	C0597170
28277189	121	126	CXCL5	T116,T123	C1955899
28277189	130	148	CXC-type chemokine	T116,T129	C0282553
28277189	181	206	granulocytic immune cells	T025	C0018183
28277189	210	239	binding to its receptor CXCR2	T044	C1149468
28277189	251	256	CXCL5	T116,T123	C1955899
28277189	259	264	CXCR2	T116,T129,T192	C0527994
28277189	291	300	oncogenic	T116,T123	C0029005
28277189	314	319	human	T016	C0086418
28277189	320	327	cancers	T191	C0006826
28277189	356	361	CXCL5	T116,T123	C1955899
28277189	365	377	osteosarcoma	T191	C0029463
28277189	378	405	cell migration and invasion	T191	C0027627
28277189	452	470	protein expression	T045	C1171362
28277189	474	479	CXCL5	T116,T123	C1955899
28277189	498	507	increased	T081	C0205217
28277189	511	523	osteosarcoma	T191	C0029463
28277189	524	531	tissues	T024	C0040300
28277189	554	587	matched adjacent nontumor tissues	T024	C0040300
28277189	603	613	expression	T045	C1171362
28277189	617	622	CXCL5	T116,T129	C1435946
28277189	657	680	advanced clinical stage	T079	C0205563
28277189	685	695	metastasis	T046	C4255448
28277189	735	740	CXCL5	T116,T123	C1955899
28277189	741	758	expression levels	T081	C3244092
28277189	783	792	increased	T081	C0205217
28277189	796	808	osteosarcoma	T191	C0029463
28277189	809	819	cell lines	T025	C0085983
28277189	831	837	Saos-2	T025	C0085983
28277189	839	843	MG63	T025	C0085983
28277189	845	849	U2OS	T025	C0085983
28277189	855	861	SW1353	T025	C0085983
28277189	891	908	normal osteoblast	T025	C0029418
28277189	909	923	hFoB1.19 cells	T025	C0029418
28277189	925	935	U2OS cells	T025	C0085983
28277189	949	960	transfected	T045	C0314641
28277189	966	971	CXCL5	T028	C1332819
28277189	974	988	specific siRNA	T114,T123	C1099354
28277189	992	1006	overexpression	T045	C1514559
28277189	1007	1014	plasmid	T114,T123	C0032136
28277189	1016	1025	Knockdown	T063	C2350567
28277189	1029	1034	CXCL5	T028	C1332819
28277189	1049	1059	suppressed	T169	C1260953
28277189	1060	1064	U2OS	T025	C0085983
28277189	1065	1092	cell migration and invasion	T191	C0027627
28277189	1111	1125	overexpression	T045	C1514559
28277189	1129	1134	CXLC5	T116,T123	C1955899
28277189	1159	1181	migration and invasion	T191	C0027627
28277189	1185	1195	U2OS cells	T025	C0085983
28277189	1217	1226	exogenous	T169	C0205228
28277189	1227	1232	CXCL5	T116,T123	C1955899
28277189	1233	1242	treatment	T169	C0039798
28277189	1273	1278	CXCL5	T116,T123	C1955899
28277189	1281	1295	overexpressing	T045	C1514559
28277189	1296	1310	hFoB1.19 cells	T025	C0029418
28277189	1334	1356	migration and invasion	T191	C0027627
28277189	1360	1370	U2OS cells	T025	C0085983
28277189	1410	1415	CXCL5	T116,T123	C1955899
28277189	1419	1423	U2OS	T025	C0085983
28277189	1424	1451	cell migration and invasion	T191	C0027627
28277189	1465	1474	paracrine	T039	C0597170
28277189	1547	1552	CXCL5	T116,T123	C1955899
28277189	1571	1583	osteosarcoma	T191	C0029463
28277189	1600	1609	oncogenic	T116,T123	C0029005
28277189	1618	1630	osteosarcoma	T191	C0029463
28277189	1631	1641	metastasis	T046	C4255448
28277189	1654	1659	CXCL5	T116,T123	C1955899
28277189	1673	1682	potential	T080	C3245505
28277189	1683	1701	therapeutic target	T169	C0205245
28277189	1706	1718	osteosarcoma	T191	C0029463
28277189	1719	1728	treatment	T169	C0039798